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Abstract 
Review on Mediastinal gray zone lymphoma, with 
data on the genes involved. 
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Identity 
Other names 
MGZL (mediastinal gray zone lymphoma) 
Clinics and pathology 
Disease 
The new WHO lymphoma classification introduced 
the provisional category of B-cell lymphoma, 
unclassifiable with features that are intermediate 
between diffuse large cell lymphoma (DLBCL) and 
classical Hodkgin lymphoma (CHL) to encompass 
cases that do not fulfill the morphological and/or 
phenotypic criteria for primary mediastinal B-cell 
lymphoma (PMBL) or nodular sclerosis Hodgkin 
lymphoma (NSHL) in the mediastinum but exhibit 
transitional features between these two entities. 
(Swerdlow S, et al., 2008; Savage KJ, et al., 2003; 
Rosenwald A, et al., 2003).  
Mediastinal gray zone lymphoma (MGZL) in a rare 
and new entity that shares clinical characteristics 
with PMBCL and NSHL. Historically, these patients 
were often included in series of Hodgkin-like 
anaplastic large cell lymphoma, which is a 
heterogeneous group. (Zinzani PL, et al., 1998; 
Grant C, et al., 2011). 
Epidemiology 
MGZL is more frequently seen in young men, with 
a median patient age of 30 years. (Traverse-Glehen 
A, et al., 2005; Rieger M, et al., 2011). 
Clinics 
The patients present a mediastinal mass larger than 
10 cm, and most of 50% of them are associated with 
elevated LDH. A minority of patients had extranodal 
involvement or pleural or pericardial effusions. Also, 
patients had low peripheral blood absolute 
lymphocyte counts (ALCs) at the time of 
presentation. (Poppema S et al., 2005). 
Treatment 
Their indeterminate pathobiology has led to 
uncertainty about what the optimal therapeutic 
strategy should be in MGZL. MGZLs are often 
found to be refractory to different chemotherapy 
regimens used in either DLBCL or CHL such as R-
CHOP, R-CHOEP, ABVD, BEACOPP. Although 
patients with MGZL have been treated as 
aggressively as patients with B-cell lymphoma, they 
generally exhibit worse outcomes that patients with 
PMBCL. (Wilson W, et al., 2014, Song H, et al., 
2016).  
Lacking other options either R-CHOP or DA-
EPOCH-R have been regarded as the most suitable 
treatments courses for patients with MGZL since 
those who did not receive these regimen as frontline 
therapy displayed disease progression. 
For relapses, salvage chemotherapy followed by 
high-dose stem cell transplantation may be 
considered. Allogeneic transplantation in another 
option, but outcomes in patients with MGZL are 
inferiors to that of PMBL. 
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Prognosis 
The association of a Hodgkin-like 
microenvironment and the poor outcomes in MGZL 
raise the hypothesis that a predominant HL-like 
morphology and/or phenotype may also be 
associated with a worse outcome. 
Additionally, the intensity of CD15, CD68, CD209 
or Bcl-6 staining on the malignant MGZL cells is  
associated with poor prognosis. (Wilson W, et al., 
2014, Song H, et al., 2016). 
Genetics 
Note 
Gains of 2p15, 9p24 and 12q24 were detected by 
PCR amplification in PMBL and NSHL tumor cells, 
supporting the hypothesis of pathogenic relationship 
between these two entities. (Joos S, et al., 1996; Joos 
S, et al., 2000).  
In PMBL and in NSHL tumor cells, within the 
smallest commonly amplified regions (2p15 and 
9p24), two genes were identified, the REL and JAK2 
oncogenes. REL in involved in the NF-kB signaling 
pathway, which has been shown to be deregulated in 
cHL before. JAK2, which is important for cytokine 
signaling, plays a crucial role in PMBL and NSHL 
pathogenesis. (Joos S, et al., 2003).  
On the basis of a gene expression analysis it has been 
identified that a dendritic cell gene expression 
signature that distinguished MGZL and NSHL from 
PMBL. This signature includes CD209, which 
encodes DC-SIGN, a marker of dendritic cells and 
activated macrophages. Interestingly, DC-SIGN 
gene expression was significantly associated with 
poor survival in NSHL, suggesting that it may be a 
biomarker of macrophage activity in MGZL. 
(Dunleavy K, et al., 2013; Wilson W, et al., 2014).  
MGZL shows a methylation profile related to but 
different from that of both PMBL and NSHL.  The 
profile falls somewhere between the methylation 
profile of PMBL and NHSL.   A unique feature 
found in MGZL is the hypomethylation of HOXA5 
(DNA-binding transcription factor which may 
regulate gene expression, morphogenesis, and 
differentiation), but the importance of this finding 
for the pathogenesis of MGZL is still unknown. 
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